Fabiotics Co., Ltd., founded in 2024, is a leading China- based biotechnology company dedicated to delivering microbial solutions for human health in an evolving environment. 

The company has been awarded the titles of “Innovative Startup” and “Science & Technology Startup” in China, selected for the “Hundred Talents Program” of Fujian Province, and received a Merit Award at the 2025 China Entrepreneurship and Innovation Competition. 

Fabiotics operates an in-house laboratory in Xiamen and a joint laboratory with the Institute of Urban Environment, Chinese Academy of Sciences (IUE, CAS). It collaborates with INRAE (France), Yale University, Fudan University, Lanzhou University, Xiamen University, and owns a proprietary strain collection comprising more than 10,000 diverse strains. The company also works with partner manufacturing facilities across South, East, and North China, with a combined annual capacity exceeding 100 tons of lyophilized powders. Its flagship strains include DePlastox™ PD01, the world’s first human-derived strain with clinical evidence for microplastic excretion and detoxification.